ICP-723 for Advanced Solid Tumors

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Advanced Solid TumorsICP-723 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new drug for people with cancer who have no other options. They will test how well the drug works and if it has any side effects.

Eligible Conditions
  • Advanced Solid Tumors

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 8 Secondary · Reporting Duration: through study completion, an average of 1.5 years.

Year 4
Apparent clearance (CL/F)
Apparent volume of distribution (Vz/F)
Area under the plasma concentration-time curve (AUC0-∞ and AUC0-t)
Disease control rate (DCR) determined using RECIST 1.1 criteria.
Half-life (t1/2)
Objective response rate (ORR) determined using RECIST 1.1 criteria.
Peak concentration (Cmax)
Time to reach peak concentration (Tmax)
Year 5
Incidence and severity of dose-limiting toxicity (DLT), adverse events (AEs), and serious adverse events (SAEs). Frequency of dose interruptions, reductions and intensity

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

ICP-723
1 of 1

Experimental Treatment

30 Total Participants · 1 Treatment Group

Primary Treatment: ICP-723 · No Placebo Group · Phase 1

ICP-723
Drug
Experimental Group · 1 Intervention: ICP-723 · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: through study completion, an average of 1.5 years.

Who is running the clinical trial?

InnoCare Pharma Inc.Lead Sponsor
Jun ZhangPrincipal InvestigatorUniversity of Kansas Medical / Cancer Centers
4 Previous Clinical Trials
5,529 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 6 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have a primary CNS tumor or CNS metastases.